Field Trip reports Q4 and full-year results for fiscal 2021. Cash position of CAD$111m. Clinic revenues increased by 63% q-o-q to CAD$526,435.
Exploring the companies and themes that make up this emerging and exciting new sector
Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board
The newest member of Cybin's Clinical Advisory Board previously held a senior position with the FDA.
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
Mydecine's novel molecule, MYCO-004 is targeting multiple forms of addiction/substance abuse.
Alternatives to ATAI: Go Big Or Go Small?
Sometimes biggest is not "best". Psychedelic Stock Watch offers investors a lot of reasons why thinking SMALLER may be more profitable.
Microdosing LSD modulates the perception of time independently of other consciousness-altering effects
Lysergic acid diethylamide, or LSD, is a drug which produces a variety of cognitive, perceptual and behavioral changes in users.
Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study
Cybin completes its 51st pre-clinical molecule study, with four of these molecules already being advanced to toward clinical evaluations.
Atai IPO Day An Underwhelming Event
The much-anticipated IPO for atai Life Sciences (US:ATAI) ended up being anti-climactic instead.
Texas Will Study Benefits Of Psychedelics For Military Veterans Under Bill Enacted Without Governor’s Signature
The governor of Texas allowed a bill that will require the state to study the therapeutic potential of psychedelics to become law without his signature on Friday.
Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company
Novamind has just completed a strategic investment of US$1 million in a private psychedelics company, as part of a $25 million Series A financing.
Rainbo’s Tonya Papanikolov Believes in the Magic of Mushrooms
Tonya Papanikolov could talk about mushrooms for hours.
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
MINDCURE announces two, new ketamine-based treatment protocols: one for pain and one for depression. These new protocols will be distributed via iSTRYM.
Mydecine Unveils Artificial Intelligence Drug Discovery Program
Mydecine announces a new program to incorporate AI "machine learning" into its drug R&D.